A COVID-19 vaccine from Novavax was shown to be highly effective in a phase 3 trial, the company announced Monday.
In a study that enrolled nearly 30,000 participants in the United States and Mexico, the Novavax vaccine demonstrated 90.4 percent overall efficacy, and it also "demonstrated 100 percent protection against moderate and severe disease," the company said.
"It's very important for the world's population to have, yet again, another highly efficacious vaccine that looks in its trial to have a good safety profile," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said, The Washington Post reports.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Novavax shots "may be the most tolerable yet tested," the Post also reported, with common side effects being fatigue, headaches, and muscle pain. In the U.S., Novavax might not seek emergency use authorization from the Food and Drug Administration until September, and given the U.S. has sufficient vaccine supply, it's possible the FDA could tell the company to apply for a full license instead, The New York Times reports.
But Novavax CEO Stanley Erck told The Wall Street Journal that "at least in the foreseeable future, we're going to have a bigger impact" outside of the U.S, and the company has pledged 1.1 billion doses to the World Health Organization global vaccine initiative Covax, per the Post. The vaccine, then, could provide a "much-needed boost to global" vaccination efforts if approved, the Journal writes.
"Many of our first doses will go to ... low and middle-income countries, and that was the goal to begin with," Erck told The Associated Press. The vaccine also has the benefit of being able to be stored at refrigerator temperatures, ABC News reports.
Novavax says that if the vaccine is approved, it's on track to produce 100 million doses a month by the end of the third quarter of 2021 and 150 million doses a month by the end of the fourth quarter.
-
SpaceX breaks Starship losing streak in 10th testspeed read The Starship rocket's test flight was largely successful, deploying eight dummy satellites during its hour in space
-
Rabbits with 'horns' sighted across Coloradospeed read These creatures are infected with the 'mostly harmless' Shope papilloma virus
-
Lithium shows promise in Alzheimer's studySpeed Read Potential new treatments could use small amounts of the common metal
-
Scientists discover cause of massive sea star die-offSpeed Read A bacteria related to cholera has been found responsible for the deaths of more than 5 billion sea stars
-
'Thriving' ecosystem found 30,000 feet underseaSpeed Read Researchers discovered communities of creatures living in frigid, pitch-black waters under high pressure
-
New York plans first nuclear plant in 36 yearsSpeed Read The plant, to be constructed somewhere in upstate New York, will produce enough energy to power a million homes
-
Dehorning rhinos sharply cuts poaching, study findsSpeed Read The painless procedure may be an effective way to reduce the widespread poaching of rhinoceroses
-
Breakthrough gene-editing treatment saves babyspeed read KJ Muldoon was healed from a rare genetic condition
